Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691323 | 0.84 | LMNA (0.43) | KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL20096897 | 0.80 | KDM4E (0.47) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1691754 | 0.79 | KDM4E (0.53) | CTSSKDM4EPOLBTSHRALDH1A1 | |
| SCHEMBL17709304 | 0.77 | ALDH1A1 (0.53) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4040412 | 0.76 | KDM4E (0.54) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1691485 | 0.76 | ALDH1A1 (0.52) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL95926 | 0.75 | KDM4E (0.56) | KDM4EPOLBTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL15007835 | 0.74 | MCL1 (0.33) | CTSSKDM4EMCL1CTSLCTSB | |
| SCHEMBL20267540 | 0.74 | TSHR (0.47) | CTSSKDM4EPOLBCTSLCTSB | |
| SCHEMBL956809 | 0.74 | NPC1 (0.48) | CTSSMCL1CTSLTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| CN-102333770-B | P38 MAP kinase inhibitors | RESPIVERT LTD | 2015-01-28 | — | — | CN | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| CN-102333770-A | P38 map kinase inhibitors | RESPIVERT LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| EP-2370429-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CTSS 3379/4885KDM4E 4497/4885POLB 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.